Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydropalmatine
- Development stage
- Phase 2
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tetrahydropalmatine is an isoquinoline alkaloid found primarily in plants of the Corydalis and Stephania genera. It is widely used in China as a sedative and analgesic agent. Tetrahydropalmatine acts mainly as a dopamine receptor antagonist and also blocks other monoamine receptors. It has additional pharmacological actions including blockade of voltage-activated L-type calcium channels and activation of potassium channels. The compound exhibits muscle relaxant properties and has been investigated for its potential use in treating schizophrenia, drug addiction (notably cocaine use disorder), anxiety, insomnia, heart disease, liver damage, neuropathic pain, inflammatory diseases, dysmenorrhea, cancer-related symptoms, and brain edema[1][2][3][5][6][8]. Its mechanism involves modulation of dopaminergic neurotransmission as well as possible effects on GABAA receptor benzodiazepine sites[5][6]. Tetrahydropalmatine is considered non-addictive with a favorable safety profile at therapeutic doses.
- Brand names
- RotundineRotundine HCl
- Other names
- THPl-THPdl-THPlevo-tetrahydropalmatine
02
Targets
BZD site (GABA-A receptor benzodiazepine site)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on tetrahydropalmatine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydropalmatine.